Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Saturday, November 21, 2009

Get a Mammogram. No Don’t. Repeat. - NYTimes.com



Get a Mammogram. No Don’t. Repeat. - NYTimes.com

So the arguments continue to rage over risks and benefits, and over how strongly to recommend mammograms, and for whom, just as they have for decades:

RARECARE - Surveillance of Rare Cancers in Europe



Prevalence
Fifteen-year prevalence for all the rare tumours, except the Epithelial Tumours of
Cervix Uteri, were under the 50 per 100,000, that is the cut off utilized in Europe for
the definition of rare disease. By contrast, Epithelial Tumours of Oesophagus,
Pancreas, Ovary and Stomach have prevalence rates lower than 50 per 100,000 but
annual incidence rates higher than 6 per 100,000. These four tumors are then
classified as frequent according to our incidence-based definition, but rare according
to the standard EU prevalence-based criterion. All these tumours have very poor
survival and therefore low prevalence figures, even in presence of a relatively high
risk of occurrence, at least for the European population.

European Action Against Rare Cancers



European Action Against Rare Cancers

National Institutes of Health make it easier to find a clinical trial. | R.A. Bloch Cancer Foundation



"ResearchMatch will match any interested individual residing in the United States with researchers who are approved to recruit potential research volunteers through the system. After an individual has self-registered to become a volunteer, ResearchMatch’s security features ensure that personal information is protected until volunteers authorize the release of their contact information to a specific study that may be of interest to them. Volunteers are notified electronically when they are a possible match and then make the decision regarding the release of their contact information. It also will promote choice as there are no obligations on the volunteer to participate in studies."

National Institutes of Health make it easier to find a clinical trial



Steve Dunn's CancerGuide: Second Opinions: Why, When, and Who



Steve Dunn is no longer with us, but his words live on.

Diagnosis and staging of primary ovarian cancer: Correlation between PET/CT, Doppler US, and CT or MRI



Alcohol and gynecological cancers: an overview



In conclusion, the current body of evidence, which is inadequate for several sites, suggests no association between alcohol consumption and risk of gynecological cancers.

What It Will Take to Embrace Participatory Medicine: One Patient’s View



Lorig

What It Will Take to Embrace Participatory Medicine: One Patient’s View



Lorig

Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations - Climacteric



Hormone replacement therapy after breast cancer: attitudes of women eligible in a randomized trial - Climacteric



A must read: The Senior Practitioner - Lapham’s Quarterly



The Senior Practitioner - Lapham’s Quarterly

Reirradiation to the abdomen for gastrointestinal malignancies